Delivery of heterologous proteins
AssigneeSana Biotechnology, Inc.
InventorsMichael J. VOLLES, Jillian DIERX, Philip CALAFATI
Life of this patent
Estimating the term…
Abstract
Provided herein are lipid particles and compositions thereof for delivery of heterologous proteins, including genome-modifying agents, to cells.
Claims339
A lipid particle comprising a lipid bilayer enclosing a lumen and a ribonucleic acid (RNA), wherein the RNA comprises, from 5′ to 3′:
- a R element of a 5′ long terminal repeat (5′ LTR);
- a U5 element of a 5′ LTR;
- a RNA sequence encoding a gag protein or portion thereof comprising at least a gag start codon;
- a RNA sequence encoding a heterologous protein that is operably linked to the RNA sequence encoding a gag protein or portion thereof;
- and a poly-A tail,
- wherein each of the R element of the 5′ LTR, the U5 element of the 5′ LTR, and the RNA sequence encoding a gag protein or portion thereof is retroviral.
A lipid particle comprising a lipid bilayer enclosing a lumen and a ribonucleic acid (RNA), wherein the RNA comprises, from 5′ to 3′:
- a R element of a 5′ long terminal repeat (5′ LTR);
- a U5 element of a 5′ LTR;
- a gag 5′ untranslated region (UTR) or portion thereof comprising at least three nucleotides;
- a RNA sequence encoding a heterologous protein that is operably linked to the gag 5′ UTR or a portion thereof;
- and a poly-A tail,
- wherein each of the R element of the 5′ LTR, the U5 element of the 5′ LTR, and the gag 5′ UTR or portion thereof is retroviral.
A lipid particle comprising a lipid bilayer enclosing a lumen and a ribonucleic acid (RNA), wherein the RNA comprises, from 5′ to 3′:
- a R element of a 5′ long terminal repeat (5′ LTR);
- a U5 element of a 5′ LTR;
- a retroviral packaging sequence;
- a gag start codon;
- a RNA sequence encoding a heterologous protein;
- and a poly-A tail,
- wherein each of the R element of the 5′ LTR, the U5 element of the 5′ LTR, and the gag start codon is retroviral.
A lipid particle comprising a lipid bilayer enclosing a lumen and a ribonucleic acid (RNA), wherein the RNA comprises, from 5′ to 3′:
- a R element of a 5′ long terminal repeat (5′ LTR);
- a U5 element of a 5′ LTR;
- a RNA sequence encoding a viral structural protein or a portion thereof;
- a RNA sequence encoding a heterologous protein;
- and a poly-A tail,
- wherein each of the R element of the 5′ LTR and the U5 element of the 5′ LTR is retroviral.
A lipid particle comprising a lipid bilayer enclosing a lumen;
- a fusion protein comprising a viral matrix (MA) protein and a MS2 coat protein (MS2cp);
- and an RNA sequence encoding a heterologous protein.
A lipid particle comprising a lipid bilayer enclosing a lumen;
- a viral matrix (MA) protein;
- an RNA-binding protein;
- and an RNA sequence encoding a heterologous protein, wherein the RNA-binding protein is incorporated into the lipid particle as a fusion protein with the viral MA protein, and wherein the RNA sequence encoding the heterologous protein comprises a binding site for binding to the RNA-binding protein.
The lipid particle of 77, wherein the plurality of boxB binding sites comprises between or between about 1 and 50, 1 and 40, 1 and 30, 1 and 25, 1 and 20, 2 and 50, 2 and 40, 2 and 30, 2 and 25, 2 and 20, 4 and 50, 4 and 40, 4 and 30, 4 and 25, 4 and 20, 5 and 50, 5 and 40, 5 and 30, 5 and 25, 5 and 20, 6 and 50, 6 and 40, 6 and 30, 6 and 25, 6 and 20, 10 and 50, 10 and 40, 10 and 30, 10 and 25, 10 and 20, 12 and 50, 12 and 40, 12 and 30, 12 and 25, 12 and 20, 15 and 50, 15 and 40, 15 and 30, 15 and 25, or 15 and 20 boxB binding sites.
A lipid particle comprising a lipid bilayer enclosing a lumen;
- a viral matrix (MA) protein;
- a MS2 coat protein (MS2cp);
- and an RNA sequence encoding a heterologous protein, wherein the MS2cp is incorporated into the lipid particle as a fusion protein with the viral MA protein, and wherein the RNA sequence encoding the heterologous protein comprises a MS2cp-binding loop for binding to MS2cp.
A lipid particle comprising a lipid bilayer enclosing a lumen a fusion protein comprising a viral matrix (MA) protein and a heterologous protein.
A lipid particle comprising a lipid bilayer enclosing a lumen;
- a viral matrix (MA) protein;
- and a heterologous protein, wherein the heterologous protein is incorporated into the lipid particle as a fusion protein with the viral MA protein.
A lipid particle comprising a lipid bilayer enclosing a lumen;
- a fusion protein comprising a viral envelope glycoprotein and an RNA-binding protein;
- and an RNA sequence encoding a heterologous protein, wherein the RNA sequence encoding the heterologous protein comprises a binding site for binding to the RNA-binding protein.
A lipid particle comprising a lipid bilayer enclosing a lumen;
- a fusion protein comprising a VSV-G protein or a functional variant thereof and an RNA-binding protein;
- and an RNA sequence encoding a heterologous protein, wherein the RNA sequence encoding the heterologous protein comprises a binding site for binding to the RNA-binding protein.
A method of producing a lipid particle comprising a lipid bilayer enclosing a lumen and a viral ribonucleic acid (RNA), comprising:
- (1) providing a host cell comprising (a) a nucleic acid sequence selected from the group consisting of:
- a 5′ long terminal repeat (5′ LTR);
- a psi packaging signal sequence;
- a gag start codon;
- a RNA sequence encoding a heterologous protein;
- a 3′ long terminal repeat (3′ LTR);
- or a combination thereof;
- and (b) a nucleic acid sequence encoding a protein selected from the group consisting of gag, pol, rev, tat, a viral envelope glycoprotein, or a combination thereof;
- and
- (2) culturing the host cell under conditions to induce packaging of the lipid particle.
A method of producing a lipid particle comprising a lipid bilayer enclosing a lumen and viral ribonucleic acid (RNA), comprising:
- (1) providing a host cell comprising (a) a RNA sequence encoding a heterologous protein and a viral structural protein or a portion thereof;
- and (b) a nucleic acid sequence encoding a protein selected from the group consisting of gag, pol, rev, tat, a viral envelope glycoprotein, or a combination thereof;
- and
- (2) culturing the host cell under conditions to induce packaging of the lipid particle.
A method of producing a lipid particle comprising a lipid bilayer enclosing a lumen and a viral transfer plasmid, comprising
- (1) providing a host cell comprising (a) a nucleic acid sequence encoding a fusion protein comprising a viral matrix (MA) protein and an RNA binding protein;
- (b) a nucleic acid sequence encoding a heterologous protein;
- and (c) a nucleic acid sequence encoding a protein selected from the group consisting of gag, pol, Rev, Tat, a viral envelope glycoprotein, or a combination thereof;
- and
- (2) culturing the host cell under conditions to induce packaging of the lipid particle.
A method of producing a lipid particle comprising a lipid bilayer enclosing a lumen and a viral transfer plasmid, comprising:
- (1) providing a host cell comprising (a) a nucleic acid sequence encoding a fusion protein comprising a viral matrix (MA) protein and a MS2 coat protein (MS2cp);
- (b) a nucleic acid sequence encoding a heterologous protein;
- and (c) a nucleic acid sequence encoding a protein selected from the group consisting of gag, pol, Rev, Tat, a viral envelope glycoprotein, or a combination thereof;
- and
- (2) culturing the host cell under conditions to induce packaging of the lipid particle.
A method of producing a lipid particle comprising a lipid bilayer enclosing a lumen and a viral transfer plasmid, comprising:
- (1) providing a host cell comprising (a) a nucleic acid sequence encoding a fusion protein comprising a viral envelope glycoprotein and an RNA binding protein;
- (b) a nucleic acid sequence encoding a heterologous protein;
- and
- (2) culturing the host cell under conditions to induce packaging of the lipid particle.
A method of producing a lipid particle comprising a lipid bilayer enclosing a lumen and a viral transfer plasmid, comprising:
- (1) providing a host cell comprising (a) a nucleic acid sequence encoding a fusion protein comprising viral matrix (MA) protein and a heterologous protein;
- and (b) a nucleic acid sequence encoding a protein selected from the group consisting of gag, pol, Rev, Tat, a viral envelope glycoprotein, or a combination thereof;
- and
- (2) culturing the host cell under conditions to induce packaging of the lipid particle.
A deoxyribonucleic acid (DNA) sequence encoding a gag start codon and a heterologous protein.
A DNA sequence encoding a viral matrix (MA) protein, an RNA binding protein, and a cleavage site between the portions of the DNA sequence encoding the MA protein and the RNA binding protein.
A DNA sequence encoding a viral matrix (MA) protein, a MS2 coat protein (MS2cp), and a cleavage site between the portions of the DNA sequence encoding the MA protein and the MS2cp.
A DNA sequence encoding a viral envelope glycoprotein, an RNA binding protein, and a cleavage site between the portions of the DNA sequence encoding the viral envelope glycoprotein and the RNA binding protein.
The DNA sequence of claim 312, which encodes a fusion protein comprising, from 5′ to 3′, the viral MA protein and the heterologous protein.
A transfer plasmid comprising a promoter operably linked to a RNA sequence encoding a gag protein or portion thereof comprising at least a gag start codon;
- a RNA sequence encoding a heterologous protein that is linked to the RNA sequence encoding a gag protein or portion thereof;
- and a 3′ long terminal repeat (3′ LTR).
A transfer plasmid comprising a promoter operably linked to a ribonucleic acid (RNA), wherein the RNA comprises, from 5′ to 3′:
- a 5′ long terminal repeat (5′ LTR);
- a gag 5′ untranslated region (UTR) or portion thereof comprising at least three nucleotides;
- a RNA sequence encoding a heterologous protein that is linked to the gag 5′ UTR or a portion thereof;
- and a 3′ long terminal repeat (3′ LTR).
A transfer plasmid comprising a promoter operably linked to a ribonucleic acid (RNA), wherein the RNA comprises, from 5′ to 3′:
- a 5′ long terminal repeat (5′ LTR);
- a retroviral packaging sequence;
- a gag start codon;
- a RNA sequence encoding a heterologous protein;
- and a 3′ long terminal repeat (3′ LTR).
A transfer plasmid comprising a promoter operably linked to a nucleic acid sequence encoding a fusion protein comprising a viral matrix (MA) protein and a MS2 coat protein (MS2cp).
A transfer plasmid comprising a promoter operably linked to a nucleic acid sequence encoding a viral matrix (MA) protein and a heterologous protein.
Dependencies are inferred from the claim text.